{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '14.', 'ADMINISTRATIVE MATTERS', '14.1.', 'Regulatory and Ethical Compliance', 'This clinical study was designed and shall be implemented and reported in accordance with the', 'ICH Harmonised Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local', 'regulations (including European Directive 2001/20/EC and United States Code of Federal', 'Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki.', '14.2.', 'Ethics Committees', 'The protocol, the proposed ICF, and any other relevant records must be reviewed and approved', 'by a properly constituted ethics committee (eg, IRB) before study start.', '14.3.', 'Regulatory Authority Approval', 'Before implementing this study, the protocol must be approved by relevant, competent', 'regulatory authorities.', '14.4.', 'Protocol Adherence', 'Prior to study start, the Investigator is required to sign a protocol signature page confirming', 'his/her agreement to conduct the study in accordance with the instructions and procedures found', 'in this protocol. Investigators attest they will apply due diligence to avoid protocol deviations.', 'All data points listed in this protocol and in the eCRFs are considered required. Any deviations', 'from the protocol are to be recorded in the eCRF. All significant protocol deviations will be', 'recorded and reported in the CSR.', '14.5.', 'Amendments to the Protocol', 'Any change or addition to the protocol can only be made in a written protocol amendment that', 'must be provided by the Sponsor and approved by regulatory authorities where required, and the', 'ethics committee (eg, IRB). Only amendments that are required for patient safety may be', 'implemented prior to ethics committee (eg, IRB) approval. Notwithstanding the need for', 'approval of formal protocol amendments, the Investigator is expected to take any immediate', 'action required for the safety of any patient included in this study, even if this action represents a', 'deviation from the protocol. In such cases, the Sponsor should be notified of this action, and the', 'ethics committee (eg, IRB) at the study site should be informed according to local regulations but', 'not later than 10 working days.', '14.6.', 'Informed Consent', 'Eligible patients may only be included in the study after providing written (witnessed, where', 'required by law, ethics committee [eg, IRB], or regulation), ethics committee (eg, IRB)-approved', 'informed consent.', 'Informed consent must be obtained before conducting any study-specific procedures. Note age', 'on date consent is signed. Procedures that are part of the clinical routine evaluations during the', 'initial diagnostic work-up of the patient may be performed before the ICF is signed and dated (ie,', 'procedures that are not specific to the conduct of the study).', 'Confidential', 'Page 104', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Informed consent must also be obtained for SVdX/SdX patients before conducting any study-', 'specific procedures for SVdX/SdX treatment.', 'The process of obtaining informed consent should be documented in the patient source', 'documents. A copy of the ICF must be given to the patient or to the person signing the form on', 'behalf of the patient. The Investigator or designee must record the date when the study ICF was', 'signed in the medical records of the patient. The name and role of the witness, if required, should', 'also be documented.', 'The Sponsor will provide to Investigators, in a separate document, a proposed ICF that is', 'appropriate for this study and complies with the ICH GCP guideline and regulatory', 'requirements. Any changes to this ICF suggested by the Investigator must be agreed to by', 'Karyopharm before submission to the ethics committee (eg, IRB). If an ethics committee', 'requests substantive changes to the ICF as part of their review, those revisions must also be', 'submitted to Karyopharm for consideration prior to re-submission back to the IRB. A copy of the', 'approved version must be provided to Karyopharm after ethics committee (eg, IRB) approval.', '14.7.', 'Patient Confidentiality and Disclosure', 'The Investigator must ensure anonymity of all patients; patients must not be identified by names', 'in any documents submitted to Sponsor or its representative. Signed ICFs and patient enrollment', 'logs must be kept strictly confidential.', '14.8.', 'Study Documentation, Data Collection and Storage, and Study', 'Monitoring and Auditing Procedures', '14.8.1.', 'Study Documentation, Record Keeping, and Retention of Documents', 'Each participating site will maintain appropriate medical and research records for this study, in', 'compliance with Section 4.9 of ICH GCP E6, and regulatory and institutional requirements. Each', 'site will permit authorized representatives of the Sponsor and regulatory agencies to examine', '(and when required by applicable law, to copy) anonymized clinical records for the purposes of', 'quality assurance reviews, audits, and evaluation of the study safety and progress.', 'Source data include all information, original records of clinical findings, observations, or other', 'activities in a clinical study necessary for the reconstruction and evaluation of the study.', 'Data collection is the responsibility of the clinical study staff at the site under the supervision of', 'the site Investigator. The study eCRF is the primary data collection instrument for the study. The', 'Investigator is responsible for the accuracy, completeness, and timeliness of the data reported in', 'the eCRFs and all other required reports. Data reported in the eCRFs, which are derived from', 'source documents, should be consistent with the source documents or the discrepancies should', 'be explained. All data requested in the eCRF must be recorded. Any missing data must be', 'explained. For eCRFs an audit trail will be maintained by the system.', 'The Investigator/institution should maintain study documents as specified in Essential', 'Documents for the Conduct of a Clinical Trial (ICH GCP E6 Section 8) and as required by', 'applicable regulations and/or guidelines. The Investigator/institution should take measures to', 'prevent accidental or premature destruction of these documents.', 'Confidential', 'Page 105', 'Version 4.0']\n\n###\n\n", "completion": "END"}